The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
Open accessAbstract
Background: It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis. Objectives: To investigate whether the time between discontinuation of anti-fibrotic therapy and lung transplant in patients with idiopathic pulmonary fibrosis affects the risk of complications. Methods: We assessed intra-operative and post-transplant complications among patients with idiopathic pulmonary fibrosis who underwent lung transplant and had been treated with nintedanib or pirfenidone continuously for ⩾ 90 days at listing. Patients were grouped according to whether they had a shorter (⩽ 5 medication half-lives) or longer (> 5 medication half-lives) time between discontinuation of anti-fibrotic medication and transplant. Five half-lives corresponded to 2 days for nintedanib and 1 day for pirfenidone. Results: Among patients taking nintedanib ( n = 107) or pirfenidone ( n = 190), 211 (71.0%) had discontinued anti-fibrotic therapy ⩽ 5 medication half-lives before transplant. Anastomotic and sternal dehiscence occurred only in this group (anastomotic: 11 patients [5.2%], p = 0.031 vs patients with longer time between discontinuation of anti-fibrotic medication and transplant; sternal: 12 patients [5.7%], p = 0.024). No differences were observed in surgical wound dehiscence, length of hospital stay, or survival to discharge between groups with a shorter versus longer time between discontinuation of anti-fibrotic therapy and transplant. Conclusion: Anastomotic and sternal dehiscence only occurred in patients with idiopathic pulmonary fibrosis who discontinued anti-fibrotic therapy < 5 medication half-lives before transplant. The frequency of other intra-operative and post-transplant complications did not appear to differ depending on when anti-fibrotic therapy was discontinued. Registration: clinicaltrials.gov NCT04316780: https://clinicaltrials.gov/ct2/show/NCT04316780
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“nintedanib-treated patients that remained on therapy had a 12-month FVC that was 106mL (95% CI, 34–178, P=0.004) higher than the pirfenidone-treated group in multivariable models [50].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [50]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, there was no difference in FVC between two antifibrotic groups at month 24. Similarly, no difference in hospitalizations or death was found between the two groups.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Stewart, S., Fishbein, M. C., Snell, G. I., Berry, G. J., Boehler, A., Burke, M. M., Glanville, A., Gould, F. K., Magro, C., Marboe, C. C., et al. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.10.017 · Cited by 2,442
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Development of the New Lung Allocation System in the United States
Egan, T. M., Murray, S., Bustami, R. T., Shearon, T. H., McCullough, K. P., Edwards, L. B., Coke, M. A., Garrity, E. R., Sweet, S. C., Heiney, D. A., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01276.x · Cited by 767
Cited by
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 60
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
Yedgarian, N., Agopian, J., Flaig, B., Hajjar, F., Karapetyan, A., Murthy, K., Patrikyan, A., Tomas, K., Tumanyan, K., Nasiri, M. J., et al. (2025) · Biomolecules · doi:10.3390/biom15071036 · Cited by 9
Chen, L., Wang, J., & Qu, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1680118 · Cited by 3
Non-pharmacological Management of Fibrosing Interstitial Lung Diseases
Kaenmuang, P., Yip, W. H., Kahai, R., & Fabbri, L. (2025) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2025.0136 · Cited by 3
Metadata
- Authors
- Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., Leonard, T. B., Bender, S., Barakat, A., Breeze, J. L., & LaCamera, P.
- Affiliations
- Massachusetts General Hospital (US)
- Brigham and Women's Hospital (US)
- Duke University (US)
- University of Pennsylvania (US)
- Washington University in St. Louis (US)
- University of Iowa (US)
- Temple University (US)
- Cleveland Clinic (US)
- Boehringer Ingelheim (United States) (US)
- ILD Collaborative, Boston, MA, USA
- Tufts University (US)
- St. Elizabeth's Medical Center (US)
- Corresponding author
- LaCamera, Peter
- ORCID
- Venue
- Therapeutic Advances in Respiratory Disease
- Publisher
- SAGE Publications
- Published
- 2023-01
- Volume
- 17
- Pages
- 17534666231165912-17534666231165912
- ISSN
- 1753-4658 (ISSN-L)
- 1753-4666
- PMC
- PMC10126649
- OpenAlex
- W4366351092
- Semantic Scholar
- 012578e84dc56c8540133fff1c2847bce994e1f8
- Cited by
- 8
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Respiratory Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- This study was funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI).
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, lung transplantation, antifibrotic therapy, nintedanib, pirfenidone, anastomotic leakage, sternal dehiscence, post-transplant complications, surgical wound complications
- MeSH terms
- Fibrosis, Humans, Lung Transplantation, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1177/17534666231165912
- The paper
- Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., Leonard, T. B., Bender, S., Barakat, A., Breeze, J. L., & LaCamera, P. (2023). Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231165912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.